BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33882342)

  • 1. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation.
    Story CM; Wang T; Bhatt VR; Battiwalla M; Badawy SM; Kamoun M; Gragert L; Brown V; Baxter-Lowe LA; Marsh SGE; Gadalla SM; Schetelig J; Mytilineos J; Miklos D; Waller EK; Kuxhausen M; Spellman S; Lee S; Paczesny S; Lansford JL; Vincent BG; Riches ML; Armistead PM;
    Transplant Cell Ther; 2021 Jul; 27(7):591-599. PubMed ID: 33882342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens.
    Lansford JL; Dharmasiri U; Chai S; Hunsucker SA; Bortone DS; Keating JE; Schlup IM; Glish GL; Collins EJ; Alatrash G; Molldrem JJ; Armistead PM; Vincent BG
    Blood Adv; 2018 Aug; 2(16):2052-2062. PubMed ID: 30115642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies].
    Yu S; Dai M; Sun J; Fan Z; Huang F; Zhang Y; Jiang Q; Zhou H; Xu D; Meng F; Liu Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):826-30. PubMed ID: 25246252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
    Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry.
    Gillis N; Padron E; Wang T; Chen K; DeVos JD; Spellman SR; Lee SJ; Kitko CL; MacMillan ML; West J; Tang YH; Teng M; McNulty S; Druley TE; Pidala JA; Lazaryan A
    Transplant Cell Ther; 2023 Oct; 29(10):640.e1-640.e8. PubMed ID: 37517612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
    Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
    Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
    Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.
    Fleischhauer K; Shaw BE; Gooley T; Malkki M; Bardy P; Bignon JD; Dubois V; Horowitz MM; Madrigal JA; Morishima Y; Oudshoorn M; Ringden O; Spellman S; Velardi A; Zino E; Petersdorf EW;
    Lancet Oncol; 2012 Apr; 13(4):366-74. PubMed ID: 22340965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
    Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted minor histocompatibility antigen typing to estimate graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Nie D; Zhang J; Liu L; Li X; Wang J; Wang J; Zhang W; Chen J; Zhou X; Tan Y; Liu H; Tian W
    Bone Marrow Transplant; 2021 Dec; 56(12):3024-3028. PubMed ID: 34531543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
    Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT.
    Olsen KS; Jadi O; Dexheimer S; Bortone DS; Vensko SP; Bennett S; Tang H; Diiorio M; Saran T; Dingfelder D; Zhu Q; Wang Y; Haiman CA; Pooler L; Sheng X; Webb A; Pasquini MC; McCarthy PL; Spellman SR; Weimer E; Hahn T; Sucheston-Campbell L; Armistead PM; Vincent BG
    Blood Adv; 2023 May; 7(9):1635-1649. PubMed ID: 36477467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.
    Saber W; Opie S; Rizzo JD; Zhang MJ; Horowitz MM; Schriber J
    Blood; 2012 Apr; 119(17):3908-16. PubMed ID: 22327226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.